目的:本研究旨在评估眼部不良事件的风险,包括视网膜动脉阻塞(RAO),视网膜静脉阻塞(RVO),非感染性葡萄膜炎(NIU),非传染性巩膜炎(NIS),视神经炎(ON),缺血性视神经病变(ION),眼运动神经麻痹(OMCNP),2019年冠状病毒病(COVID-19)疫苗接种后。
方法:基于人群的自我对照病例系列方法:本研究利用了韩国国家健康保险局和韩国疾病控制和预防机构提供的全国性索赔和疫苗接种数据。从整个5200万韩国人口中,事件RAO的患者,RVO,前NIU,非前NIU,NIS,ON,ION,或2021年1月至2022年3月的OMCNP被包括在内。疫苗接种后危险期定义为COVID-19疫苗接种后长达56天。RAO的相对发病率比率(IRR),RVO,前NIU,非前NIU,NIS,ON,ION,使用条件泊松回归测量风险期和OMCNP。
结果:该研究包括6,590、70,120、137,958、17,921、15,492、2,039、49,089和11,312例RAO事件,RVO,前NIU,非前NIU,NIS,ON,ION,和OMCNP,分别。早期风险期(0-28天)的IRR(95%置信区间)为0.95(0.88-1.01),0.96(0.94-0.98),0.93(0.91-0.94),0.93(0.89-0.96),0.96(0.92-1.01),1.04(0.92-1.18),0.98(0.95-1.00),和0.91(0.86-0.96),分别。在晚期风险期(29-56天),内部收益率为0.96(0.89-1.03),0.93(0.91-0.96),0.96(0.95-0.98),1.00(0.95-1.04),0.96(0.91-1.01),1.00(0.87-1.15),1.01(0.98-1.04),和0.95(0.90-1.01),分别。
结论:COVID-19疫苗接种并未增加RAO事件的风险,RVO,前NIU,非前NIU,NIS,ON,ION,或OMCNP在疫苗接种后期间。
OBJECTIVE: This study aimed to assess the risk of ocular adverse events, including retinal artery occlusion (RAO), retinal vein occlusion (RVO), non-infectious uveitis (NIU), non-infectious scleritis (NIS), optic neuritis (ON), ischemic optic neuropathy (ION), and ocular motor cranial nerve palsy (OMCNP), following coronavirus disease 2019 (COVID-19) vaccination.
METHODS: Population-based self-controlled
case series METHODS: This study utilized nationwide claims and vaccination data provided by the Korea National Health Insurance Service and Korea Disease Control and Prevention Agency. From the entire South Korean population of 52 million individuals, patients with incident RAO, RVO, anterior NIU, non-anterior NIU, NIS, ON, ION, or OMCNP between January 2021 and March 2022 were included. The post-vaccination risk period was defined as up to 56 days after COVID-19 vaccination. The relative incidence rate ratios (IRRs) for RAO, RVO, anterior NIU, non-anterior NIU, NIS, ON, ION, and OMCNP during the risk periods were measured using conditional Poisson regression.
RESULTS: The study included 6,590, 70,120, 137,958, 17,921, 15,492, 2,039, 49,089, and 11,312 cases of incident RAO, RVO, anterior NIU, non-anterior NIU, NIS, ON, ION, and OMCNP, respectively. The IRRs (95% confidence interval) during the early risk period (0-28 days) were 0.95 (0.88-1.01), 0.96 (0.94-0.98), 0.93 (0.91-0.94), 0.93 (0.89-0.96), 0.96 (0.92-1.01), 1.04 (0.92-1.18), 0.98 (0.95-1.00), and 0.91 (0.86-0.96), respectively. In the late risk period (29-56 days), the IRRs were 0.96 (0.89-1.03), 0.93 (0.91-0.96), 0.96 (0.95-0.98), 1.00 (0.95-1.04), 0.96 (0.91-1.01), 1.00 (0.87-1.15), 1.01 (0.98-1.04), and 0.95 (0.90-1.01), respectively.
CONCLUSIONS: COVID-19 vaccination did not increase the risk of incident RAO, RVO, anterior NIU, non-anterior NIU, NIS, ON, ION, or OMCNP during the post-vaccination period.